ACTUALIZACIÓN EN EL ABORDAJE DEL CÁNCER DE PRÓSTATA METASTÁSICO HORMONO--SENSIBLE HORMONO ÁLVARO PINTO Servicio de Oncología Médica Hospital Universitario La Paz IdiPAZ, Madrid
ADT + docetaxel: a new standard of care for men with mcnpc and high metastatic burden (2015) Presented By Karim Fizazi at 2017 ASCO Annual Meeting
LATITUDE: A phase 3, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos <br />in newly diagnosed high-risk metastatic hormone-naïve prostate cancer patients Presented By Karim Fizazi at 2017 ASCO Annual Meeting
Overall study design of LATITUDE Presented By Karim Fizazi at 2017 ASCO Annual Meeting
Treatment arms were well balanced Presented By Karim Fizazi at 2017 ASCO Annual Meeting
Statistically significant 38% risk reduction of death Presented By Karim Fizazi at 2017 ASCO Annual Meeting
OS benefit consistently favorable across subgroups Presented By Karim Fizazi at 2017 ASCO Annual Meeting
Statistically significant 53% risk reduction of radiographic progression or death Presented By Karim Fizazi at 2017 ASCO Annual Meeting
Statistically significant improvement in all secondary end points Presented By Karim Fizazi at 2017 ASCO Annual Meeting
Statistically significant 70% risk reduction of time to PSA progression Presented By Karim Fizazi at 2017 ASCO Annual Meeting
Statistically significant 30% risk reduction of time to pain progression Presented By Karim Fizazi at 2017 ASCO Annual Meeting
Statistically significant 58% risk reduction of time to subsequent <br />PC therapy Presented By Karim Fizazi at 2017 ASCO Annual Meeting
Summary of adverse events Presented By Karim Fizazi at 2017 ASCO Annual Meeting
Adverse events of special interest Presented By Karim Fizazi at 2017 ASCO Annual Meeting
Conclusions Presented By Karim Fizazi at 2017 ASCO Annual Meeting
Conclusions Presented By Karim Fizazi at 2017 ASCO Annual Meeting
Slide 24 Presented By Karim Fizazi at 2017 ASCO Annual Meeting
Slide 1 Presented By Nicholas James at 2017 ASCO Annual Meeting
Docetaxel & ZA comparisons: patients Presented By Nicholas James at 2017 ASCO Annual Meeting
Abiraterone comparison: patients Presented By Nicholas James at 2017 ASCO Annual Meeting
Inclusion criteria Presented By Nicholas James at 2017 ASCO Annual Meeting
Outcome measures Presented By Nicholas James at 2017 ASCO Annual Meeting
Multi-arm multi-stage (MAMS) design Presented By Nicholas James at 2017 ASCO Annual Meeting
Accrual Presented By Nicholas James at 2017 ASCO Annual Meeting
Slide 30 Presented By Nicholas James at 2017 ASCO Annual Meeting
Slide 38 Presented By Nicholas James at 2017 ASCO Annual Meeting
Slide 42 Presented By Nicholas James at 2017 ASCO Annual Meeting
Slide 47 Presented By Nicholas James at 2017 ASCO Annual Meeting
Slide 53 Presented By Nicholas James at 2017 ASCO Annual Meeting
Slide 63 Presented By Nicholas James at 2017 ASCO Annual Meeting
Slide 70 Presented By Nicholas James at 2017 ASCO Annual Meeting
Slide 76 Presented By Nicholas James at 2017 ASCO Annual Meeting
Comparing CHAARTED High Volume Patients and LATITUDE Patients Presented By Eric Small at 2017 ASCO Annual Meeting
Comparing LATITUDE and CHAARTED Patients Presented By Eric Small at 2017 ASCO Annual Meeting
Comparing LATITUDE Patients and CHAARTED High Volume Patients Presented By Eric Small at 2017 ASCO Annual Meeting
Comparing Overall Survival Across Studies Presented By Eric Small at 2017 ASCO Annual Meeting
Slide 20 Presented By Eric Small at 2017 ASCO Annual Meeting
Slide 22 Presented By Eric Small at 2017 ASCO Annual Meeting
Slide 26 Presented By Eric Small at 2017 ASCO Annual Meeting
Comparing Overall Survival Across Studies Presented By Eric Small at 2017 ASCO Annual Meeting
Take Homes from Latitude Presented By Eric Small at 2017 ASCO Annual Meeting
PROS & CONS ABIRATERONA DOCETAXEL Menor toxicidad Pacientes unfit para QT Elección del paciente Menor coste Menor duración de tratamiento Exceso de presión antiandrogénica? Toxicidad financiera Paciente fit para QT? Seguimiento corto Exceso de toxicidad para obtener resultados similares? No todos son fit
CONCLUSIONES TENEMOS DOS ESTÁNDARES DE TRATAMIENTO? EN QUÉ BASAREMOS LA ELECCIÓN? Toxicidad Forma de presentación Coste Conveniencia (iv vs oral) Secuenciación posterior Lo que nos dejen poner
MUCHAS GRACIAS POR SU ATENCIÓN ÁLVARO PINTO Servicio de Oncología Médica Hospital Universitario La Paz IdiPAZ, Madrid